J. M. Boyle

V. Orphanos2
M. Fox2
Y. Hey2
M. Santibanez-Koref2
G. McGown2
2V. Orphanos
2M. Fox
2Y. Hey
2M. Santibanez-Koref
2G. McGown
Learn More
Previous work has indicated a role for p53 in cell cycle control, genomic stability and cellular responses to DNA-damaging agents. However, few data are available for human fibroblasts heterozygous for defined germline mutations in TP53. We report studies on 25 strains derived from 12 families with Li-Fraumeni syndrome (LFS) and 18 strains from normal(More)
Previous work has implicated putative tumour-suppressor (ts) genes at 6q27 and a broad region at 6p12-q23. Here we report the results of a coded, randomised study of allelic imbalance at 12 loci on 6q on 40 pairs of coded tumour-blood pairs from patients with ovarian tumours. Our results provide clear evidence for the involvement of different regions of 6q(More)
To define regions of deletion of chromosome 6q in breast cancer, we scored 18 (CA)n microsatellites for allelic imbalance (AI) in 42 paired blood/tumour samples. Heterozygosity frequencies of the markers in the sample population ranged from 31% to 92% (mean 68%). Two regions of the chromosome arm showed AI values greater than the background range of 10-22%(More)
The clinical problem of tumour non-responsiveness is the main factor limiting the success of anticancer chemotherapy, with both inherent and acquired resistance playing a role. The basis of acquired drug resistance has been extensively studied in rodent and human cells in culture using single or multistep selections, but often with drug concentrations in(More)
European Communities, with the aim of evaluating screening tests in chemical car-cinogenesis. The first section contains papers dealing with general strategy and appraisal of current programmes for carcinogenesis screening in U.S.A. and Japan and the methods being used to evaluate short term tests. A word of warning is rightly sounded in this section by(More)
  • 1